Patented product, technological innovation – Tarcine BioMed, a subsidiary of BAHEAL Pharmaceutical Group, unveiled its nasopharyngeal cancer diagnostic series at the 15th Health Management Academic Conference of the Chinese Medical Association
发布时间：2024-11-29 浏览次数：403次 作者：
From November 22nd to 24th, 2024, the "17th Health Service Industry Conference and the 15th Health Management Academic Conference of the Chinese Medical Association" was held in Beijing. It was hosted by the Chinese Medical Association and the Health Management Branch of the Chinese Medical Association, organized by the Beijing Medical Association and the Health Management Branch of the Beijing Medical Association, and co-organized by the China Health Promotion Foundation and the "Chinese Journal of Health Management" of the Chinese Medical Association.
The product unveiled this time is the third-generation nasopharyngeal cancer auxiliary diagnostic reagent independently developed by Tarcine BioMed, which has been successfully approved for marketing by the National Medical Products Administration.
The meeting invites Wang Kejian, a researcher from the Pharmaceutical Research and Development Center of Tsinghua Yangtze River Delta Research Institute in Zhejiang, to share an academic presentation titled "Promoting the Coordinated Development of Early Screening and Scientific Research through Physical Examination Centers - Nasopharyngeal Carcinoma Screening from Rta Protein to Immune Group Library". The presentation will delve into the deep mechanism of EBV infection and nasopharyngeal carcinoma occurrence, and clarify the biological significance of EB virus antibodies such as Rta-IgG in the early diagnosis of nasopharyngeal carcinoma.
For over a decade, the triple test model pioneered by Tarcine BioMed, which combines Rta-IgG with EA-IgA and VCA-IgA, has emerged as the primary screening approach for nasopharyngeal cancer, benefiting numerous patients and establishing a solid reputation among clients in the field of nasopharyngeal cancer screening. Looking ahead, based on the third-generation, entirely new products and utilizing a fully automated magnetic particle chemiluminescence platform, the results will be even more stable and better meet diverse clinical diagnostic needs. Tarcine BioMed remains committed to the pursuit of "earlier, more accurate, and more reliable" products, and will continue to contribute its efforts to the cancer early screening market in China's physical examination sector.